BIOPHARMA
By
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could GSK’s Twice-Yearly Asthma Drug Change Long-Term Treatment for Patients?
United States GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved its new…
Inductive Bio and Amgen Collaborate With ARPA-H to Advance AI-Based Alternatives to Animal Toxicology Testing
United States Inductive Bio, a New York–based artificial intelligence company focused on drug discovery, has been awarded up…
